1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Medigen Vaccine Biologics Corporation

Medigen Vaccine Biologics Corporation

6547.TWO
Medigen Vaccine Biologics CorporationTW flagTaipei Exchange
45.35
TWD
+0.30
- -
14.91BMarket Cap

Total Valuation

Medigen Vaccine Biologics Corporation carries a market capitalization of 14.91B, placing it among publicly traded companies globally. Its enterprise value stands at 10.90B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap14.91B
Enterprise Value10.90B

Share Statistics

Medigen Vaccine Biologics Corporation currently has 328.75M shares outstanding.

Shares Outstanding328.75M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 20.20, and the price-to-book ratio stands at 4.12.

PE RatioN/A
PS Ratio20.20
PB Ratio4.12
P/TBV Ratio3.58
P/FCF Ratio8,002.95
P/OCF Ratio-252.38

Enterprise Valuation

EV / Sales17.77
EV / EBITDAN/A
EV / EBITN/A
EV / FCF1,052.70

Financial Position

Medigen Vaccine Biologics Corporation maintains a current ratio of 12.77, meaning it holds 12.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.15, indicating elevated leverage, while an interest coverage ratio of -30.19 demonstrates limited ability to service its debt obligations.

Current Ratio12.77
Quick Ratio9.60
Debt / Equity8.15
Debt / EBITDA-1.07
Interest Coverage-30.19

Financial Efficiency

Return on Equity (ROE)-9.07
Return on Assets (ROA)-6.79
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover0.59

Stock Price Statistics

Medigen Vaccine Biologics Corporation's stock has declined approximately -7.8252% over the past 52 weeks. The 50-day moving average sits at 50.62, while the 200-day moving average is 40.92.

Beta (5Y)N/A
52-Week Price Change-7.8252%
50-Day Moving Average50.62
200-Day Moving Average40.92
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Medigen Vaccine Biologics Corporation generated 613.17M in revenue and converted that into -281.71M in net income, yielding earnings per share of -0.86. EBITDA reached -265.69M, while operating income came in at -265.69M.

Revenue613.17M
Gross Profit364.67M
Operating Income-265.69M
Pretax Income-281.71M
Net Income-281.71M
EBITDA-265.69M
EBIT-265.69M
Earnings Per Share (EPS)-0.86

Balance Sheet

Medigen Vaccine Biologics Corporation holds 1.78B in cash and equivalents against 283.44M in total debt, resulting in a net debt position of -592.04M. Total book value stands at 3.01B, with working capital of 2.18B providing operational flexibility.

Cash & Cash Equivalents1.78B
Total Debt283.44M
Net Debt-592.04M
Equity (Book Value)3.01B
Book Value Per Share9.16
Working Capital2.18B

Cash Flow

Medigen Vaccine Biologics Corporation produced -49.09M in operating cash flow over the past twelve months. After subtracting -50.63M in capital expenditures, free cash flow totaled -99.72M - equivalent to -0.30 per share.

Operating Cash Flow-49.09M
Capital Expenditures-50.63M
Free Cash Flow-99.72M
FCF Per Share-0.30

Margins

Medigen Vaccine Biologics Corporation operates with a gross margin of 59.47, reflecting its pricing power and cost economics. The operating margin of -43.33 and net profit margin of -45.94 provide insight into operational efficiency.

Gross Margin59.47
Operating Margin-43.33
Pretax Margin-45.94
Profit Margin-45.94
EBITDA Margin-43.33

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield0.32
FCF Yield0.01

Stock Splits

Medigen Vaccine Biologics Corporation's most recent stock split took place on August 3, 2022 with a 500:741 split ratio.

Last Split Date8/3/2022
Split Ratio500:741

Scores

Medigen Vaccine Biologics Corporation posts an Altman Z-Score of 16.85, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score16.85